Difference between revisions of "Histrelin (Vantas)"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *10 | + | *2004-10-12: Initial FDA approval in the palliative treatment of advanced [[prostate cancer]]. ''(Based on Schlegel 2006)'' |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 22:07, 4 May 2023
General information
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 2004-10-12: Initial FDA approval in the palliative treatment of advanced prostate cancer. (Based on Schlegel 2006)
Patient drug information
Also known as
- Generic name: histrelin acetate
- Brand names: Supprelin, Vantas